<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041247</url>
  </required_header>
  <id_info>
    <org_study_id>IPROTECT1</org_study_id>
    <secondary_id>2013-002735-23</secondary_id>
    <nct_id>NCT02041247</nct_id>
  </id_info>
  <brief_title>Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection</brief_title>
  <official_title>Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnaVirVax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnaVirVax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV
      patients receiving standard of care antiretroviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-3S antibodies titer</measure>
    <time_frame>From D0 to week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tolerance to 6 vaccinations of VAC-3S</measure>
    <time_frame>From D0 to week 72</time_frame>
    <description>safety parameter changes according to the DAIDS (Division of Acquired Immunodeficiency Syndrome) adverse events (AEs) grading table.Safety parameters include adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, viral load, CD4 and CD8 counts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood inflammatory marker concentrations</measure>
    <time_frame>From D0 to week 72</time_frame>
    <description>Inflammatory markers include: Highly sensitive C-reactive protein (hsCRP), Highly sensitive Recombinant human interleukin 6 (hsIL-6), Soluble CD14 (sCD14), Soluble CD163 (sCD163), D-dimer, Interferon (IFN)-gamma inducible protein 10 (IP-10), Tumor necrosis factor receptor 1 (sTNFR1) and 2 (sTNFR2), Immunoglobulin G (IgG),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenic characteristics of VAC-3S</measure>
    <time_frame>From D0 to week 72</time_frame>
    <description>anti-3S antibody titers and determination of anti-3S antibody isotypes and avidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte phenotype markers</measure>
    <time_frame>From D0 to week 72</time_frame>
    <description>Phenotype markers include: Nkp44L expression on the surface of CD4+ T lymphocytes, phenotypic markers of of lymphocyte differentiation and activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary virological effects</measure>
    <time_frame>From D0 to week 72</time_frame>
    <description>3S gp41 sequences and proviral HIV reservoir</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>VAC-3S 16µg/administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC-3S Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC-3S 32 µg/administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC-3S 64 µg/administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAC-3S</intervention_name>
    <description>VAC-3S is administered via intra-muscular route in the arm.</description>
    <arm_group_label>VAC-3S 16µg/administration</arm_group_label>
    <arm_group_label>VAC-3S Placebo</arm_group_label>
    <arm_group_label>VAC-3S 32 µg/administration</arm_group_label>
    <arm_group_label>VAC-3S 64 µg/administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented HIV-1 infection,

          2. Adults &gt; 18 and &lt; 60 years of age,

          3. Able and willing to comply with the protocol, including availability for all scheduled
             study visits,

          4. Provided a signed written informed consent,

          5. Meets study screening physical, medical history and laboratory assessments (defined
             below),

          6. On stable antiretroviral therapy that is consistent with the current standard of care
             for at least 12 months prior to study screening,

          7. Plasma HIV RNA &lt; 50 cps/mL during the previous 12 months,

          8. CD4+ T cell count at screening &gt; 200 and &lt; 500 cells/mm3,

          9. Adequate hematology, biochemistry, and metabolic blood tests defined as being less
             than grade 2 according to the Division of AIDS Adverse Events (See Appendix 23.1),
             except for the numeration of CD4 and for the numeration of lymphocytes,

         10. Adequate hepatic and renal function defined as being less than Grade 2 according to
             the Division of AIDS Adverse Events (See Appendix 23.1),

         11. Female patients of childbearing age with one documented negative blood pregnancy tests
             between Screening and Visit 1/Month 0; Female patient of childbearing potential must
             be receiving two forms of effective contraception and must be willing to use them
             throughout the study duration. These include oral, transdermal, systemic or implant
             contraception birth control, intra-uterine devices (IUD), abstinence and double
             barrier method such as diaphragm with spermicidal gel or other recommended double
             barrier method,

         12. Affiliated with the National Medical Insurance System,

         13. Believed by investigator to be able and willing to comply with the requirements of the
             study protocol and will be available for all scheduled visits at the study site.

        Exclusion Criteria:

          1. Not meeting all of the inclusion criteria listed above,

          2. Administration of any investigational drug or device within 28 days prior to
             screening,

          3. Prior history of an AIDS-defining event in the past 5 years,

          4. Active co-infection with either Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or
             any other active viral hepatitis co-infection,

          5. Any acute or clinically significant infections within the past month,

          6. Known allergy or intolerance to components of VAC-3S as documented through medical
             records or via patient interview,

          7. Chronic active liver disease as documented by any of the following laboratory
             assessments: ultrasound, clinical assessment, liver biopsy or equivalent non-invasive
             methods,

          8. Receipt of any known vaccinations within the past 1 month prior to screening,

          9. Receipt of any agent in the past 12 months that exerts a known immunological effect
             (e.g. includes but not limited to IL-2, IL-7, growth hormone…),

         10. Patients with Insulin Dependent Diabetes Mellitus, patients receiving anti-diabetic
             treatment, anticoagulants (excluding daily &quot;baby-dose&quot; aspirin) or daily NSAIDs within
             one week of study enrollment,

         11. Receipt of any contraindicated medications listed in Appendix 23.2,

         12. History of or active auto-immune disease,

         13. Acute or chronic psychiatric conditions which in the opinion of the investigator would
             need continual psychological support and/or medications incompatible with study
             participation,

         14. Patients with contraindications to intramuscular injections including, but not limited
             to, patients with thrombocytopenia and/or anomalies of the coagulation system,

         15. Any uncontrolled chronic or acute condition that in the opinion of the investigator
             would compromise safety of the patient or the ability to properly administer the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Ho Tsong Fang, DVM PhD</last_name>
    <role>Study Director</role>
    <affiliation>InnaVirVax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Sud Francilien</name>
      <address>
        <city>Corbeil-Essonne</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jürgen Rockstroh</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerd Fätkenheuer</name>
      <address>
        <city>Köln</city>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

